Nurix Therapeutics
NRIX
126 hedge funds and large institutions have $436M invested in Nurix Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 43 reducing their positions, and 13 closing their positions.
884% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $225K
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
16% more capital invested
Capital invested by funds: $377M → $436M (+$59.1M)
2% more funds holding
Funds holding: 123 → 126 (+3)
2.1% more ownership
Funds ownership: 89.86% → 91.97% (+2.1%)
5% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$7.1M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$2.86M |
| 3 |
BlackRock
New York
|
+$2.33M |
| 4 |
Millennium Management
New York
|
+$1.86M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$3.16M |
| 2 |
Goldman Sachs
New York
|
-$2.22M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.09M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$1.62M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$1.37M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
E
126
Ergoteles
New York
| – | -$431K | -48,494 | Closed |
|
127
Ameriprise
Minneapolis,
Minnesota
| – | -$361K | -40,649 | Closed |
|
128
Renaissance Technologies
New York
| – | -$257K | -28,900 | Closed |
|
129
SG Americas Securities
New York
| – | -$211K | -23,725 | Closed |
|
130
Marshall Wace
London,
United Kingdom
| – | -$191K | -21,497 | Closed |
|
|
BP
131
BBR Partners
New York
| – | -$186K | -20,988 | Closed |
|
132
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| – | -$135K | -15,177 | Closed |
|
133
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$121K | -14,000 | Closed |
|
|
JF
134
Jump Financial
Chicago,
Illinois
| – | -$107K | -12,100 | Closed |
|
|
NFGH
135
Nan Fung Group Holdings
Kai Tak,
Hong Kong
| – | -$102K | -11,500 | Closed |
|
|
ACM
136
Aquatic Capital Management
Chicago,
Illinois
| – | -$10K | -1,100 | Closed |
|
|
TWA
137
TCI Wealth Advisors
Tucson,
Arizona
| – | -$3.15K | -355 | Closed |
|
|
PA
138
Parallel Advisors
San Francisco,
California
| – | -$266 | -30 | Closed |
|
NRIX Hedge Fund Activity: Q2 2023 in Review
126 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2023, worth a combined $436M — up 16% from $377M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NRIX positions and 13 closed out — a net gain of 3 holders — while 45 added to existing stakes and 43 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $7.1M. The largest seller was State Street, cutting an estimated $3.16M.
- 126 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2023, up from 123 in Q1 2023.
- Funds reported $436M of Nurix Therapeutics stock for Q2 2023, up 16% quarter-over-quarter.
- 16 funds opened new Nurix Therapeutics positions in Q2 2023 and 13 closed out, a net change of +3 holders.
- The largest Nurix Therapeutics buyer in Q2 2023 was Wasatch Advisors, an estimated $7.1M added.
- The largest Nurix Therapeutics seller in Q2 2023 was State Street, an estimated $3.16M sold.
Based on aggregated 13F filings for Q2 2023.